Daewon Pharmaceutical Co., Ltd.

KSE 003220.KS

Daewon Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 204.44 M

Daewon Pharmaceutical Co., Ltd. Shareholders' Equity is USD 204.44 M for the year ending December 31, 2023, a 3.12% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Daewon Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 198.25 M, a 8.01% change year over year.
Daewon Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 183.55 M, a -6.54% change year over year.
Daewon Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 196.40 M, a 11.17% change year over year.
Daewon Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 176.66 M, a 7.68% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 003220.KS

Daewon Pharmaceutical Co., Ltd.

CEO	Mr. Seung-Ryel Baek
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	386 Cheonhodae-ro
Employees	1,260
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics Soft Drinks & Sodas

Description

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years